Abstract
Administration of the synthetic retinoid Fenretinide lowers circulating retinol and may thus affect night vision. We have recently shown that plasma retinol levels below 100 ng/ml are associated with moderate alterations of the dark adaptometry test. To identify which patients are more likely to experience a decrease of plasma retinol under this threshold, we measured plasma levels of retinol, Fenretinide, and its metabolite 4-MPR in a cohort of 28 women receiving Fenretinide at the daily dose of 200 mg and studied their relationship with clinical characteristics such as age, menstrual status, body mass index, and time on treatment. Our results show that patients aged over 55 years with a higher percentage of adipose tissue had higher plasma concentrations of 4-MPR, which turned out to be the major determinant of the retinol decrease. This subgroup may thus deserve careful ophthalmological surveillance.
| Original language | English |
|---|---|
| Pages (from-to) | 507-510 |
| Number of pages | 4 |
| Journal | Cancer Epidemiology Biomarkers and Prevention |
| Volume | 3 |
| Issue number | 6 |
| Publication status | Published - 1994 |
Fingerprint
ASJC Scopus subject areas
- Epidemiology
- Oncology
Cite this
Factors affecting plasma retinol decline during long-term administration of the synthetic retinoid Fenretinide in breast cancer patients. / Torrisi, Rosalba; Parodi, Stefano; Fontana, Vincenzo; Rondanina, Gabriella; Formelli, Franca; Costa, Alberto; Boccardo, Francesco; Decensi, Andrea.
In: Cancer Epidemiology Biomarkers and Prevention, Vol. 3, No. 6, 1994, p. 507-510.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Factors affecting plasma retinol decline during long-term administration of the synthetic retinoid Fenretinide in breast cancer patients
AU - Torrisi, Rosalba
AU - Parodi, Stefano
AU - Fontana, Vincenzo
AU - Rondanina, Gabriella
AU - Formelli, Franca
AU - Costa, Alberto
AU - Boccardo, Francesco
AU - Decensi, Andrea
PY - 1994
Y1 - 1994
N2 - Administration of the synthetic retinoid Fenretinide lowers circulating retinol and may thus affect night vision. We have recently shown that plasma retinol levels below 100 ng/ml are associated with moderate alterations of the dark adaptometry test. To identify which patients are more likely to experience a decrease of plasma retinol under this threshold, we measured plasma levels of retinol, Fenretinide, and its metabolite 4-MPR in a cohort of 28 women receiving Fenretinide at the daily dose of 200 mg and studied their relationship with clinical characteristics such as age, menstrual status, body mass index, and time on treatment. Our results show that patients aged over 55 years with a higher percentage of adipose tissue had higher plasma concentrations of 4-MPR, which turned out to be the major determinant of the retinol decrease. This subgroup may thus deserve careful ophthalmological surveillance.
AB - Administration of the synthetic retinoid Fenretinide lowers circulating retinol and may thus affect night vision. We have recently shown that plasma retinol levels below 100 ng/ml are associated with moderate alterations of the dark adaptometry test. To identify which patients are more likely to experience a decrease of plasma retinol under this threshold, we measured plasma levels of retinol, Fenretinide, and its metabolite 4-MPR in a cohort of 28 women receiving Fenretinide at the daily dose of 200 mg and studied their relationship with clinical characteristics such as age, menstrual status, body mass index, and time on treatment. Our results show that patients aged over 55 years with a higher percentage of adipose tissue had higher plasma concentrations of 4-MPR, which turned out to be the major determinant of the retinol decrease. This subgroup may thus deserve careful ophthalmological surveillance.
UR - http://www.scopus.com/inward/record.url?scp=0028068071&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028068071&partnerID=8YFLogxK
M3 - Article
C2 - 8000302
AN - SCOPUS:0028068071
VL - 3
SP - 507
EP - 510
JO - Cancer Epidemiology Biomarkers and Prevention
JF - Cancer Epidemiology Biomarkers and Prevention
SN - 1055-9965
IS - 6
ER -